Write in a clean editor, then format for Neuropsychopharmacology Reports in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Neuropsychopharmacology Reports is a peer-reviewed journal published by Wiley, covering Schizophrenia research and treatment, Neurotransmitter Receptor Influence on Behavior, Treatment of Major Depression.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Neuropsychopharmacology Reports 12 (3): 45–58.
Formats any DOI in Neuropsychopharmacology Reports style. No sign-up. |
| Publishes research in | Schizophrenia research and treatment Neurotransmitter Receptor Influence on Behavior Treatment of Major Depression Tryptophan and brain disorders Attention Deficit Hyperactivity Disorder |
| ISSN | 2574-173X |
| Citation impact (2-yr) | 2.3 |
| h-index | 30 |
| i10-index | 164 |
| Total citations | 5,605 |
| Article processing charge | $2,700 |
| Open access | Yes |
| Top institutions publishing here | National Center of Neurology and Psychiatry |
| Journal website | onlinelibrary.wiley.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
AIM: Aging is thought to coincide with gradual and progressive changes in brain function and behavior over the lifetime. Our previous meta-analytic study reported age-related behavioral changes from young to middle age in male C57BL/6J mice. However, the previous study had some limitations that could affect the generalizability of the findings because of the potential…
BACKGROUND: Antiseizure drugs (ASDs) are the primary therapy for epilepsy, with more than 20 drugs introduced into clinical practice to date. These drugs are typically grouped by their mechanisms of action and therapeutic spectrum. This article aims to educate non-neurologists and medical students about the new frontiers in the pharmacology of ASDs and presents the…
BACKGROUND: Individuals infected by the novel coronavirus (SARS-CoV-2) have experienced different psychiatric manifestations during the period of infectivity and post-COVID-19 infection. Fatigue and anhedonia are among the frequently reported manifestations after recovery from this novel viral pandemic, leading to early evaluation of those patients and proper management of their complaints which have a drastic burden…
Abstract Aims Synaptic Ras GTPase‐activating protein 1 (SYNGAP1) regulates synaptic plasticity through AMPA receptor trafficking. SYNGAP1 mutations have been found in human patients with intellectual disability (ID) and autism spectrum disorder (ASD). Almost every individual with SYNGAP1 ‐related ID develops epilepsy, and approximately 50% have ASD. SYNGAP1 ‐related ID is estimated to account for at…
